The Sarcoma Program at Washington University is a nationally recognized leader in the care of patients with soft tissue and bone sarcomas.
Our team of physicians and healthcare professionals are experienced in the diagnosis and treatment of this rare and complex disease. We are actively involved in clinical and basic science research as we work towards advancing the care of patients with sarcoma.
Make an Appointment
Referring physicians or patients can call 314-747-1171 to schedule a consultation with one of our Sarcoma Program physicians.
Make a gift to Sarcoma Research
Sarcomas
Our team focuses on the diagnosis and treatment of soft tissue and bone sarcoma in the adolescent and young adult (AYA) and adult patient populations. We are dedicated to the treatment of sarcomas of all types and at all stages. The following are the most commonly diagnosed bone and soft tissue sarcomas:
- Osteosarcoma
- Ewing’s sarcoma
- Myxofibrosarcoma
- Chondrosarcoma
- Leiomyosarcoma
- Liposarcoma
Our Treatment Approach
Our team focuses on the diagnosis and treatment of soft tissue and bone sarcoma in the adolescent and young adult (AYA) and adult patient populations. We are dedicated to the treatment of sarcomas of all types and at all stages. The following are the most commonly diagnosed bone and soft tissue sarcomas:
Treatment Team
Brian Van Tine, MD, PhD
Dr. Van Tine is the director of the Sarcoma Program and focuses on the care of patients with soft tissue and bone sarcomas. His laboratory studies the molecular and genetic events underlying sarcoma pathogenesis. We work to identify metabolic deficiencies in sarcoma that can be used as therapeutic opportunities.
Angela Hirbe, MD, PhD
Dr. Hirbe is focused on the care of AYA patients with bone and soft tissue sarcomas as well as patients with cancer predisposition syndromes including Neurofibromatosis Type 1 and Li Fraumeni Syndrome. Her laboratory is focused on genomics and mouse models of soft tissue sarcomas, particularly NF1-associated MPNST, with the goal of identifying drivers that can be exploited as for early cancer detection or therapeutic targeting.
Mia Weiss, MD
Dr. Weiss is dedicated to the care of patients with soft tissue and bone sarcomas. She has a particular interest in the treatment of geriatric patient populations. Her current research focuses on clinical trial development utilizing novel therapeutics for patients with early and late stage disease.
- Nicole Petrykowski DNP, FNP-C
- Sanita Burgic APRN
- Molly Sink MSN, NP-C
- Jen Wagoner, RN
- Brittanie Shetterly, RN
- Elizabeth Atkins, RN
- Jenn Seiber, RN
Research and Clinical Trials
The sarcoma team at Washington University is actively engaged in clinical trials as well as basic and translational research to improve outcomes for patients with sarcoma. Washington University is a member of the Sarcoma Alliance for Research and Collaboration (SARC), as well as the Midwest Sarcoma Trials Partnership (MWSTP).
Ongoing Clinical Trial Highlights
- ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial: This study is evaluating the efficacy and safety of ADI-PEG20, a degrader of arginine in combination with standard of care Gemcitabine and Docetaxel in patients with advanced metastatic leiomyosarcoma that have progressed on anthracycline therapy
- Sarc041 Phase 3 Abemaciclib +/-Placebo in Dedifferentiated Liposarcoma: This study is evaluating the efficacy and safety of Abemaciclib, a CDK4 inhibitor, in patients with or without previous treatment for advanced dedifferentiated liposarcoma. The study design is randomized vs placebo and is double-blind. Patients with progression of disease will cross over to open label abemaciclib.
- Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma (STRASS2): This clinical trial is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy in addition to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.